HIV Scientific Papers
TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at 48 weeks [abstract].
XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada.
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.
Effects of TH9507, a growth hormone-releasing factor (GRF) analog, on the quality of life of HIV-infected patients with abdominal fat accumulation.
Poster #L-167 presented at: the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Massachusetts, USA.
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.
J Infect Dis.
Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog.
Int J Pharm.